EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study

Xuefang Cao, Tonglei Guo, Henan Xin, Jiang Du, Chenlu Yang, Boxuan Feng, Yijun He, Lingyu Shen, Yuanzhi Di, Zihan Li, Yanxiao Chen, Jianguo Liang und 3 weitere

European Journal of Clinical Microbiology & Infectious Diseases · 2024

DOI: 10.1007/s10096-024-04777-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Xuefang Cao und 14 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Systems Biology of Pathogens, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medica…. Hauptthemen laut MEDLINE: Latent Tuberculosis, Cost-Benefit Analysis, Antitubercular Agents, Rural Population. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: The National Key R&D Program of China, The CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Several model studies suggested the implementation of latent tuberculosis infection (LTBI) testing and treatment could greatly reduce the incidence of tuberculosis (TB) and achieve the 2035 target of the "End TB" Strategy in China. The present study aimed to evaluate the cost-effectiveness of LTBI testing and TB preventive treatment among key population (≥ 50 years old) susceptible to TB at community level in China. METHODS: A Markov model was developed to investigate the cost-effectiveness of LTBI testing using interferon gamma release assay (IGRA) and subsequent treatment with 6-month daily isoniazid regimen (6H) (as a standard regimen for comparison) or 6-week twice-weekly rifapentine and isoniazid regimen (6-week H2P2) in a cohort of 10,000 adults with an average initial age of 50 years. RESULTS: In the base-case analysis, LTBI testing and treatment with 6H was dominated (i.e., more expensive with a lower quality-adjusted life year (QALY)) by LTBI testing and treatment with 6-week H2P2. LTBI testing and treatment with 6-week H2P2 was more effective than no intervention at a cost of $20,943.81 per QALY gained, which was below the willingness-to-pay (WTP) threshold of $24,211.84 per QALY gained in China. The one-way sensitivity analysis showed the change of LTBI prevalence was the parameter that most influenced the results of the incremental cost-effectiveness ratios (ICERs). CONCLUSION: As estimated by a Markov model, LTBI testing and treatment with 6-week H2P2 was cost-saving compared with LTBI testing and treatment with 6H, and it was considered to be a cost-effective option for TB control in rural China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisCost-Benefit AnalysisAntitubercular AgentsRural PopulationInterferon-gamma Release TestsIsoniazidHumansChinaMiddle AgedMaleDecision Support TechniquesFemaleAgedRifampinMarkov ChainsQuality-Adjusted Life Years

Stichwörter der Autor:innen

Cost-effectivenessLatent tuberculosis infectionMarkov modelPreventive treatmentTuberculosis

Substanzen

Antitubercular AgentsIsoniazidRifampinrifapentine

Autor:innen und Institutionen

  • NHC Key Laboratory of Systems Biology of Pathogens, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730, Beijing, People's Republic of China.
  • Key Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730, Beijing, People's…
  • Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, 100005, Beijing, China.
  • Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, 571199, Haik…
  • College of Public Health, Zhengzhou University, 450001, Zhengzhou, China.
  • Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, 100005, Beijing, China. liwang@ibms.pumc.edu.…

Förderung

  • The National Key R&D Program of China
  • The CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Cao, X., Guo, T., Xin, H., Du, J., Yang, C., Feng, B., He, Y., Shen, L., Di, Y., Li, Z., Chen, Y., Liang, J., Jin, Q., Wang, L., & Gao, L. (2024). Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04777-z

Vancouver

Cao X, Guo T, Xin H, Du J, Yang C, Feng B, et al. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04777-z

BibTeX
@article{Cao2024,
  author = {Cao, Xuefang and Guo, Tonglei and Xin, Henan and Du, Jiang and Yang, Chenlu and Feng, Boxuan and He, Yijun and Shen, Lingyu and Di, Yuanzhi and Li, Zihan and Chen, Yanxiao and Liang, Jianguo and Jin, Qi and Wang, Li and Gao, Lei},
  title = {Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  doi = {10.1007/s10096-024-04777-z}
}
Kostenlos starten →